SPASTICITY IN SPINAL-CORD INJURED PERSONS - QUANTITATIVE EFFECTS OF BACLOFEN AND PLACEBO TREATMENTS

被引:15
作者
HINDERER, SR
LEHMANN, JF
PRICE, R
WHITE, O
DELATEUR, BJ
DEITZ, J
机构
[1] UNIV WASHINGTON, DEPT REHABIL MED, SEATTLE, WA 98195 USA
[2] UNIV MICHIGAN, DEPT PHYS MED & REHABIL, ANN ARBOR, MI 48109 USA
关键词
SPASTICITY; SPINAL CORD INJURY; BACLOFEN; PLACEBO; QUANTITATIVE MEASUREMENT; SINUSOIDAL MOTION; VISCOUS STIFFNESS; ELASTIC STIFFNESS;
D O I
10.1097/00002060-199012000-00007
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Spasticity commonly occurs after a spinal cord injury and is characterized by increased resistance to passive movement of peripheral joints. This study examined the effect of an antispasticity medication on stiffness from the myotatic reflex response generated by passive sinusoidal ankle motion. A repeated measures, multiple base-line, single-subject, double-blind design was employed. The independent variable was spasticity medication treatment, where the levels were 40 mg/day and 80 mg/day of baclofen v placebo treatment. Viscous and elastic stiffness measurements were taken at the ankle joint during a placebo base-line phase and during treatment with baclofen for five adult males with traumatic spinal cord injuries. Ankle sinusoidal oscillation frequencies were from 3 to 12 Hz during test sessions. Mean viscous and elastic stiffness scores for all frequencies were calculated for each phase of the study. Randomization tests of mean changes in stiffness measurements between each treatment phase of the study failed to provide any convincing evidence of a significant treatment effect for reduction of spasticity in the traumatic spinal cord injured subjects studied. Further testing is needed to exclude potential confounding factors before this conclusion can be confirmed. The results suggest that baclofen is not a universal treatment of choice for all individuals with spasticity resulting from traumatic spinal cord injury.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 23 条
  • [1] COMPARISON OF BACLOFEN AND DIAZEPAM IN TREATMENT OF SPASTICITY
    CARTLIDGE, NE
    HUDGSON, P
    WEIGHTMAN, D
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1974, 23 (01) : 17 - 24
  • [2] ANTISPASTICITY DRUGS - MECHANISMS OF ACTION
    DAVIDOFF, RA
    [J]. ANNALS OF NEUROLOGY, 1985, 17 (02) : 107 - 116
  • [3] EVALUATION OF BACLOFEN TREATMENT FOR CERTAIN SYMPTOMS IN PATIENTS WITH SPINAL-CORD LESIONS - DOUBLE-BLIND, CROSSOVER STUDY
    DUNCAN, GW
    SHAHANI, BT
    YOUNG, RR
    [J]. NEUROLOGY, 1976, 26 (05) : 441 - 446
  • [4] BACLOFEN FOR SPASTICITY IN MULTIPLE-SCLEROSIS - DOUBLE-BLIND CROSSOVER AND 3-YEAR STUDY
    FELDMAN, RG
    KELLYHAYES, M
    CONOMY, JP
    FOLEY, JM
    [J]. NEUROLOGY, 1978, 28 (11) : 1094 - 1098
  • [5] FROM A, 1975, ACTA NEUROL SCAND, V51, P158
  • [6] GILMAN AG, 1980, PHARMACOL BASIS THER, P488
  • [7] DETERMINING OPTIMAL THERAPY - RANDOMIZED TRIALS IN INDIVIDUAL PATIENTS
    GUYATT, G
    SACKETT, D
    TAYLOR, DW
    CHONG, J
    ROBERTS, R
    PUGSLEY, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (14) : 889 - 892
  • [8] HARRIS FN, 1985, BEHAV ASSESS, V7, P121
  • [9] DOUBLE-BLIND COMPARISON OF SINGLE DOSES OF DS103-282, BACLOFEN AND PLACEBO FOR SUPPRESSION OF SPASTICITY
    HASSAN, N
    MCLELLAN, DL
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1980, 43 (12) : 1132 - 1136
  • [10] HERSEN M, 1976, SINGLE CASE EXPT DES, P35